Prostate Cancer Diagnosis
-
BiPASS Phase 3 Study: First U.S. Patient Dosed for Prostate Cancer
Telix Pharmaceuticals has dosed the first U.S. patient in its Phase 3 BiPASS trial, evaluating PSMA-PET imaging agents for prostate cancer diagnosis. The study aims to assess if combining MRI with Illuccix®/Gozellix® PSMA-PET imaging can improve accuracy and reduce the need for invasive biopsies, which are often negative. This trial seeks marketing authorization for pre-biopsy PSMA-PET imaging, potentially offering a less invasive diagnostic pathway for many patients.
